Press Release

Statement Regarding FDA Oversight of Promotion Online

PhRMA April 29, 2013

Washington, D.C. (March 31, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) Assistant General Counsel Jeffrey K. Francer issued the following statement today on the FDA’s anticipated social media guidance:

"PhRMA has engaged the Food and Drug Administration (FDA) in public discussion of how our member companies can appropriately communicate with healthcare providers and patients online, using the same tools as the FDA and the White House, including Twitter, Facebook and blogs.

"There are incredible potential public health benefits to using electronic media in healthcare, including allowing innovative companies to provide truthful, scientifically accurate FDA-regulated information.

"PhRMA has proposed responsible means to provide safety information in space-restricted media, including a universal symbol that could help lead patients to web sites that feature FDA-regulated benefit and risk information about new medicines.

"As PhRMA eagerly awaits the FDA’s guidance on this important issue, we note that FDA itself is making almost daily use of Twitter, Facebook and other social media. Clearly, social media can be used to discuss new medical advances in appropriate ways that benefit patients and healthcare professionals, and improve the public health."

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.4 billion in 2010 in discovering and developing new medicines. Industry-wide research and investment reached a record $67.4 billion in 2010.

Find PhRMA Online:

For information on how innovative medicines save lives, visit:
For information on the Partnership for Prescription Assistance, visit:
For information on ensuring the flow of medicines during public health emergencies, visit